Literature DB >> 11171908

Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease.

M A Garvey1, C Toro, S Goldstein, G Altarescu, E A Wiggs, M Hallett, R Schiffmann.   

Abstract

The authors compared stretch-evoked somatosensory evoked potentials (SEP) of 18 type 3 Gaucher disease (GD3) patients (two with progressive myoclonus epilepsy [PME]) with 22 age-matched normal controls and six patients with type 1 (nonneuronopathic) Gaucher disease (GD1). The mean P1-N2 SEP amplitude in GD3 patients was significantly larger than the SEP in controls and in GD1 patients, and there was a significant negative correlation between SEP amplitude and the IQ of GD3 patients. The authors conclude that abnormal cortical inhibition is a unifying feature of GD3 patients and correlates with the degree of cognitive deficit.

Entities:  

Mesh:

Year:  2001        PMID: 11171908     DOI: 10.1212/wnl.56.3.391

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

2.  Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Authors:  Azza Abdel Gawad Tantawy; Eman Mounir Sherif; Amira Abdel Moneam Adly; Sahar Hassanine; Amina Hafez Awad
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

Review 3.  Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.

Authors:  Emily C Daykin; Emory Ryan; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2021-01-09       Impact factor: 4.797

4.  The saccadic and neurological deficits in type 3 Gaucher disease.

Authors:  William Benko; Markus Ries; Edythe A Wiggs; Roscoe O Brady; Raphael Schiffmann; Edmond J Fitzgibbon
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

Review 5.  Progressive myoclonic epilepsy.

Authors:  Mary L Zupanc; Benjamin Legros
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648

6.  Variation in cognitive function over time in Gaucher disease type 3.

Authors:  Alta M Steward; Edythe Wiggs; Taylor Lindstrom; Somto Ukwuani; Emory Ryan; Nahid Tayebi; Tamanna Roshan Lal; Grisel Lopez; Raphael Schiffmann; Ellen Sidransky
Journal:  Neurology       Date:  2019-11-12       Impact factor: 11.800

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.